News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Seattle Genetics, Inc. (SGEN) Presents Data from Phase 1 Clinical Trial Of Antibody-Drug Conjugate (ADC) SGN-CD19A In Non-Hodgkin Lymphoma At American Society of Clinical Oncology Annual Meeting


6/2/2014 9:18:53 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

CHICAGO--(BUSINESS WIRE)--Seattle Genetics, Inc. (Nasdaq:SGEN) today will present interim phase 1 clinical data from SGN-CD19A, an antibody-drug conjugate (ADC) in development for the treatment of B-cell malignancies, at the American Society of Clinical Oncology (ASCO) 50th Annual Meeting being held May 30 to June 3, 2014 in Chicago, IL. SGN-CD19A is an ADC targeting CD19, a protein expressed on B-cell malignancies.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES